about
Recurrent, robust and scalable patterns underlie human approach and avoidanceMajor depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XLVariation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatmentQT interval and antidepressant use: a cross sectional study of electronic health recordsA double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorderThe prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey ReplicationReview of Suicide Prevention Programs: Massachusetts, United States, in Comparison with SeoulProspective studies of adverse events related to antidepressant discontinuationAntidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional researchA meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorderEfficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trialEffect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes StudyResolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitorsA comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D reportDoes comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomesPharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D studyAre antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsMicrostructural abnormalities in subcortical reward circuitry of subjects with major depressive disorderCross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depressionA mega-analysis of genome-wide association studies for major depressive disorderDepression and public health
P50
Q21136378-3B5304C4-B54E-4542-B33D-AC7023378938Q24288801-A10EC7FD-DAF9-498A-94FB-9515FEAFF6F0Q24530904-C5650FDA-0258-4732-8717-12B209E958B9Q24546379-A192051F-F74B-4088-ACCC-9B50863BCFB5Q24629713-9D61FE26-7084-4016-884E-6A389C4437CAQ24634050-A9640CAF-3974-484A-A482-12518AB5B5D0Q24670210-7158B912-3EAF-4015-9E8D-3D801B30C423Q26799932-31177779-886B-4F2A-959B-437FA9E15B1BQ28239069-6E9181D6-C625-4F01-8B89-26BA94E1F39FQ28239080-E168A830-0826-4F7E-BE44-DB9DB5195714Q28245017-5B17E44C-1890-4A77-A0D5-EC88338AFC39Q28248361-E9FD2014-7D37-46FE-87F0-1818B86DC5F7Q28252787-062A4961-CDFC-4EAC-9484-5A59894EA24DQ28260220-58D875CB-AE73-4B9B-B8DF-072D673D579DQ28261272-E421AA34-FFED-4364-946D-A5B98DB9DA2EQ28266046-4616FC50-3A55-425C-9D6A-14321E49913DQ28269390-2A866B6C-21BF-4B0E-A392-D1D96A2DA19CQ28307397-E8393C49-4FD8-4BBF-9712-2E0C122D0C7CQ28744585-8A4A7748-DC70-4974-81ED-4A2D04BC62F9Q28943274-9CFC7A0C-45F2-47D3-BB37-8E3CABEA4701Q29417093-04A59B27-3A61-4C87-AADD-1F4E149E6627Q29999595-51C1CFDC-0E73-4838-9BA2-0D2DC23C14A9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maurizio Fava
@ast
Maurizio Fava
@en
Maurizio Fava
@es
Maurizio Fava
@nl
Maurizio Fava
@sl
type
label
Maurizio Fava
@ast
Maurizio Fava
@en
Maurizio Fava
@es
Maurizio Fava
@nl
Maurizio Fava
@sl
prefLabel
Maurizio Fava
@ast
Maurizio Fava
@en
Maurizio Fava
@es
Maurizio Fava
@nl
Maurizio Fava
@sl